Gregory M. Lucas

powered by
COS Expertise®
Johns Hopkins University
School of Medicine
Medicine
Infectious Diseases
Associate ProfessorAppointed: 2006
Professional Headshot of Gregory M. Lucas

Mailing Address

1830 E. Monument Street
Room 435A
Baltimore, Maryland 21287
United States

Contact Information

Phone: (410) 614-0560
Fax: (410) 955-7889
glucas@jhmi.edu

Qualifications

Ph.D., Johns Hopkins University, Clinical Investigation, 2004.
M.D., Duke University, 1994.
B.S., University of Notre Dame, Biology, 1990.

Expertise and Research Interests

Dr Lucas is an associate professor of medicine in the division of infectious diseases. He completed his M.D. at Duke University and a PhD in clinical investigation from the Johns Hopkins Bloomberg School of Public Health. He completed his internal medicine residency and infectious diseases fellowship at The Johns Hopkins Hospital. Dr. Lucas has devoted his clinical and research career to HIV since completing his training in 2001. His research interests include integrated care for HIV-infected drug users, adherence and improving treatment outcomes in disenfranchised HIV populations, and HIV-associated kidney disease. Dr. Lucas is PI on a HRSA SPNS grant to conduct a randomized controlled trial of HIV-clinic-based buprenorphine maintenance vs. referral to an opioid treatment center in opioid-dependent HIV-infected participants. He is also PI on an R01 from NIDA to compare directly observed HIV therapy (DOT) with self-administered therapy in HIV-infected individuals receiving methadone. Dr. Lucas is a member of the HPTN and is on the protocol development committee for HPTN 058, a large-scale randomized trial to determine if buprenorphine maintenance therapy plus risk-reduction counseling is more effective than detoxification plus counseling in preventing HIV seroconversion in Chinese and Thai injection drug users.

Memberships

American College of Physicians
HIV Medical Association
Infectious Diseases Society of America

Honors and Awards

2004, Delta Omega Honorary Society in the Public Health, Alpha Chapter, Johns Hopkins University
1994, A.O.A. Medical Honor Society, Duke University

Previous Positions

2001-2006, Assistant Professor, Johns Hopkins University, School of Medicine, Medicine, Infectious Diseases

Funding Received

  • National Institute on Drug Abuse: Directly administered HIV therapy in methadone clinics, 2005 to 2010.
  • Health Resources and Service Administration: Randomized trial of HIV-clinic-based buprenorphine vs. referred substance abuse care, 2004 to 2009.
  • National Institute on Drug Abuse: Directly observed antiretroviral therapy in drug users, 2002 to 2007.

Publications

  • Atta MG, Deray G, Lucas GM (Nov 2008) Antiretroviral nephrotoxicities., Seminars in nephrology, 28 (6), 563-75 Abstract
  • Burkey MD, Wilson LE, Moore RD, Lucas GM, Francis J, Gebo KA (Nov 2008) The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era., HIV medicine, 9 (10), 858-62 Abstract
  • Moore RD, Gebo KA, Lucas GM, Keruly JC (Oct 2008) Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 47 (8), 1102-4 Abstract
  • Atta MG, Lucas GM, Fine DM (Jun 2008) HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management., Expert review of anti-infective therapy, 6 (3), 365-71 Abstract
  • Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD (Jun 2008) Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races., The Journal of infectious diseases, 197 (11), 1548-57 Abstract
  • Fine DM, Perazella MA, Lucas GM, Atta MG (Mar 2008) Kidney biopsy in HIV: beyond HIV-associated nephropathy., American journal of kidney diseases : the official journal of the National Kidney Foundation, 51 (3), 504-14 Abstract
  • Riedel DJ, Gebo KA, Moore RD, Lucas GM (Feb 2008) A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort., AIDS patient care and STDs, 22 (2), 113-21 Abstract
  • Siedner MJ, Atta MG, Lucas GM, Perazella MA, Fine DM (Feb 2008) Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients., Journal of acquired immune deficiency syndromes (1999), 47 (2), 261-3 Abstract
  • Fine DM, Perazella MA, Lucas GM, Atta MG (2008) Renal disease in patients with HIV infection: epidemiology, pathogenesis and management., Drugs, 68 (7), 963-80 Abstract
  • Berliner AR, Fine DM, Lucas GM, Rahman MH, Racusen LC, Scheel PJ, Atta MG (2008) Observations on a cohort of HIV-infected patients undergoing native renal biopsy., American journal of nephrology, 28 (3), 478-86 Abstract
  • Atta MG, Fine DM, Kirk GD, Mehta SH, Moore RD, Lucas GM (Dec 2007) Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45 (12), 1625-32 Abstract
  • Celentano DD, Lucas G (Dec 2007) Optimizing treatment outcomes in HIV-infected patients with substance abuse issues., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45 Suppl 4, S318-23 Abstract
  • Fine DM, Garg N, Haas M, Rahman MH, Lucas GM, Scheel PJ, Atta MG (Nov 2007) Cocaine use and hypertensive renal changes in HIV-infected individuals., Clinical journal of the American Society of Nephrology : CJASN, 2 (6), 1125-30 Abstract
  • Lucas GM, Mehta SH, Atta MG, Kirk GD, Galai N, Vlahov D, Moore RD (Nov 2007) End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004., AIDS (London, England), 21 (18), 2435-43 Abstract
  • Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD (Aug 2007) Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy., AIDS patient care and STDs, 21 (8), 564-74 Abstract
  • Spire B, Lucas GM, Carrieri MP (Aug 2007) Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST)., The International journal on drug policy, 18 (4), 262-70 Abstract
  • Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N (May 2007) Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users., AIDS care, 19 (5), 637-45 Abstract
  • Gebo KA, Burkey MD, Lucas GM, Moore RD, Wilson LE (Dec 2006) Incidence of, risk factors for, clinical presentation, and 1-year outcomes of infective endocarditis in an urban HIV cohort., Journal of acquired immune deficiency syndromes (1999), 43 (4), 426-32 Abstract
  • Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE (Dec 2006) Buprenorphine use: the international experience., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 Suppl 4, S197-215 Abstract
  • Sullivan LE, Bruce RD, Haltiwanger D, Lucas GM, Eldred L, Finkelstein R, Fiellin DA (Dec 2006) Initial strategies for integrating buprenorphine into HIV care settings in the United States., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 Suppl 4, S191-6 Abstract
  • Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, Thomas DL, Sulkowski MS (Nov 2006) Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic., AIDS (London, England), 20 (18), 2361-9 Abstract
  • Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD (Mar 2006) Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy., American journal of epidemiology, 163 (5), 412-20 Abstract
  • Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM (Feb 2006) Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003., AIDS (London, England), 20 (3), 437-44 Abstract
  • Moore RD, Keruly JC, Gebo KA, Lucas GM (Jun 2005) An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002., Journal of Acquired Immune Deficiency Syndromes (1999), 39 (2), 195-8 Abstract
  • Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, Sterling TR (Jun 2005) Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection., American Journal of Epidemiology, 161 (11), 999-1012 Abstract
  • Lucas GM (Apr 2005) Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven., The Journal of Antimicrobial Chemotherapy, 55 (4), 413-6 Abstract
  • Lucas GM, Wu AW, Cheever LW (Dec 2004) Adherence to antiretroviral therapy: an update of current concepts., Curr Hiv/aids Rep, 1 (4), 172-80 Abstract
  • Lucas GM, Gallant JE, Moore RD (Jul 2004) Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing., Aids (london, England), 18 (11), 1539-48 Abstract
  • Lucas GM, Weidle PJ, Hader S, Moore RD (Jun 2004) Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 38 Suppl 5, S409-13 Abstract
  • Lucas GM, Weidle PJ, Hader S, Moore RD (Jun 2004) Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study., Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America., 38 Suppl 5, S409-13 Abstract
  • Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD (Feb 2004) Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study., Aids (london, England), 18 (3), 541-6 Abstract
  • Lucas GM, Chaisson RE, Moore RD, Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: A 5-year cohort study, Journal of Acquired Immune Deficiency Syndromes (1999), 33(3), 321-8, July 2003
  • Lucas GM, Flexner CW, Moore RD, Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden?, Aids Patient Care and Stds, 16(11), 527-35, November 2002 Abstract
  • Lucas GM, Gebo KA, Chaisson RE, Moore RD, Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic, Aids (London, England), 16(5), 767-74, March 2002
  • Lucas GM, Chaisson RE, Moore RD, Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz, Aids (London, England), 15(13), 1679-86, September 2001
  • Lucas GM, Cheever LW, Chaisson RE, Moore RD, Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection, Journal of Acquired Immune Deficiency Syndromes: Jaids, 27(3), 251-9, 2001
  • Lucas GM, Tucker P, Merz WG, Primary cutaneous Aspergillus nidulans infection associated with a Hickman catheter in a patient with neutropenia, Clinical Infectious Diseases, 29(6), 1594-6, December 1999 Abstract
  • Lucas GM, Chaisson RE, Moore RD, Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions, Annals of Internal Medicine, 131(2), 81-7, July 1999 Abstract
  • Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD, Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes, Clinical Infectious Diseases, 26(5), 1127-33, 1998
  • White LE, Lucas G, Richards A, Purves D, Cerebral asymmetry and handedness, Nature, 368(6468), 197-8, March 1994 Abstract

Profile Details

Last Verified: 12/22/2008

COS Expertise ID #853243
Reference this profile directly: http://myprofile.cos.com/glucas